

SANDOZ CANADA chooses **SOLABS**

Canada is the sixth largest generic market in the world. It was this fact, among others, that attracted Sandoz, the prescription-generics division of Novartis, to invest in Canada to gain an attractive global growth platform in the fast-growing injectable generics business. Their FDA-approved manufacturing facility in Boucherville develops, manufactures, distributes injectable and ophthalmic generic pharmaceutical products for hospital and retail markets. Sandoz announced that it has chosen SOLABS GxP to control several of its process and document management procedures.

“This is a major development for SOLABS”, said Richard Fecteau, President and CEO. “Sandoz Canada is the internationally renowned Sandoz Centre of Excellence for injectable products since it has unique processes that require specific expertise. SOLABS GxP will be used initially to handle SOPs, IT documentation, and the change control process. Solabs Gxp is also capable of processing batch records, recipes and CAPA later but these functionalities are not presently under scope with Sandoz Canada.”

“We chose SOLABS GxP because of their understanding of the GMP environment”, stated Jacques Dion, Manager, MIS Quality and Security, “although, it would also be true to say that SOLABS competitive pricing, and the fact that SOLABS GxP has been satisfactorily used as a documentation tool during an FDA inspection of another pharmaceutical company were also major factors.” Sandoz Canada currently has 85 molecules and 350 SKUs produced under various dosage forms: injectables, ampoules and vials; ophthalmic solutions, suspensions and ointments; suppositories; oral and topical forms.

SANDOZ is a global supplier of generic pharmaceuticals operating in more than 120 countries. Sandoz Canada employs over 5450 people countrywide, most of them being located at the Boucherville facilities.

SOLABS is a practice-based solution company for GxP documents, workflow and records management. It operates a “Software as a Service” (SaaS) business model providing knowledge, best practice, consulting and IT solutions dedicated to the GxP regulated life sciences environment at all points along the drug development lifecycle. SOLABS provides a web-based platform and is able to provide global support through its network of partners, collaborators and distributors. SOLABS helps clients to recognize GxP regulatory compliance as a strategic advantage. SOLABS GxP solutions bring benefits through quickly implementing corporate solutions and cementing process workflow learnings across organisations. In a typical installation SOLABS GxP has achieved 100% labour-reduction for hard copy management (which corresponds to a 60%-80% overall reduction for GxP document management costs) and >95% cycle time reduction for physical workflow. This is complemented by full-automated traceability, real-time visibility and reduction in errors and lost documents.

**For further information
please contact:
Richard Fecteau (President/CEO)
on (514) 287-1368 #206 or
richard_fecteau@solabs.com**

